When Standard Insulin Pumps Aren't Enough: One Man's Experience with U-500 and Automated Delivery

Some people with Type 1 diabetes need much more insulin than others—a condition called severe insulin resistance. Standard insulin pumps, which hold a fixed amount of insulin, can run out quickly for these patients. U-500 regular insulin is a more concentrated form that allows more insulin to fit in the same pump reservoir, but it works differently than the rapid-acting insulins that most automated pump systems are designed for.

Until now, there has been very little published experience using U-500 in newer automated insulin delivery (AID) systems—the pumps that adjust insulin doses on their own throughout the day based on continuous glucose readings.

Doctors recently documented the case of a 46-year-old man with Type 1 diabetes and severe insulin resistance who was using about 245 units of U-500 insulin per day. He also had trouble recognizing when his blood sugar was dropping too low (impaired hypoglycemia awareness) and worked irregular overnight shifts. Before making the switch, his glucose management was moderate: his average blood sugar was 137 mg/dL, with about 75% of readings in the target range and 9% too low.

His medical team carefully transitioned him to an Omnipod 5 automated pump while continuing U-500. To make it work, they made several important adjustments: they set the insulin's active duration to 6 hours (longer than usual for rapid-acting insulins), set higher overnight glucose targets, used simplified meal announcements, and made active use of the pump's activity mode to prevent low blood sugars during his work shifts.

After 12 months on the automated system, the patient's glucose control improved. Time in range rose to 79.1% from 75%, and time spent too low decreased to 5.7% from 9%. Importantly, time spent very low (below 54 mg/dL) was only 0.4%. The automated pump was actively managing his blood sugar for more than 95% of the time.

The patient reported having fewer low blood sugar episodes that he could feel, though he still experienced some overnight lows during his work shifts. This suggests the automated system reduced—but did not eliminate—his hypoglycemia risk.

This case suggests that carefully managed use of U-500 in an automated pump system may help some people with very high insulin needs maintain therapy with a patch pump while reducing low blood sugar events. However, this is still an off-label use—meaning it is not how the pump system was originally approved or tested by regulators.

It's important to note that this is one patient's experience. Results may differ greatly for other people, and this approach requires close medical supervision by experienced doctors. It is not a standard treatment option and should only be considered for people with very specific circumstances and under expert care. Anyone considering this option should talk with their diabetes care team about whether it might be appropriate for them.

Source: Diabetes therapy : research, treatment and education of diabetes and related disorders. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.